The dual-component medication Spazmol Plus is a combination analgesic and antispasmodic formulation commonly used for managing symptom clusters where visceral pain and involuntary smooth muscle spasms occur together. This approach is relevant across domains where additional symptomatic support is needed. The combination is commonly used for managing symptoms associated with paroxysmal pain in the digestive system, as well as spastic pain and functional disorders in the biliary, urinary tracts, and female genital organs (e.g., dysmenorrhoea).

---

Management of Pain and Spasm Symptoms

Spazmol Plus helps address symptom clusters that may become intense or disruptive, especially in the gastrointestinal and genito-urinary domains. It is applied in clinical settings that involve acute or unstable symptom patterns, such as acute, intense colicky pain episodes, including renal colic (pain from kidney or urinary stones) and biliary colic (gallbladder-related pain).

It is also used to help address the pronounced manifestations of uterine cramping associated with dysmenorrhoea. This supportive approach provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.

---

Summary of Symptom Relief	Description
Symptom Cluster Managed	Visceral Pain + Involuntary Spasms
Acute Scenario	Renal or Biliary Colic
Patient Benefit	Easing overall symptom burden

Regulatory References

1. National Agency of Drug and Food Control of Indonesia (BPOM) Assessment Report

Who Can and Cannot Use Spazmol Plus?

Eligibility for Spazmol Plus (Acetaminophen/Hyoscine Butylbromide FDC) is strictly defined by regulatory documents, listing absolute prohibitions and specific restrictions.

Absolute Contraindications

Spazmol Plus is contraindicated and must not be used by patients with:

• Myasthenia Gravis or Glaucoma (especially narrow-angle).
• Mechanical obstructions of the gastrointestinal tract (e.g., paralytic ileus, megacolon, or mechanical stenosis).
• Severe hepatocellular insufficiency (Child-Pugh C) or prostatic hypertrophy with urinary retention.
• Known hypersensitivity to either active ingredient or any excipients.

Age and Conditional Eligibility

Category	Regulatory Status
Pediatric Use	Not suitable for children under 10 years of age.
Pregnancy/Lactation	Not recommended; a risk to the fetus or child cannot be excluded.
Conditional Use	Use requires caution in patients with impaired kidney function or non-severe impaired liver function, or in those prone to tachyarrhythmia.

Interactions with other medicines and products

Spazmol Plus is a combination product containing both hyoscine-N-butylbromide and paracetamol, which contributes to a diverse interaction profile.

---

Pharmacodynamic Interactions (Hyoscine-N-butylbromide component)

• Anticholinergic Agents: Concurrent use with medicines that have anticholinergic properties, such as tricyclic antidepressants, antihistamines, antipsychotics, or quinidine, may intensify side effects like dry mouth, blurred vision, constipation, or increased heart rate.
• Dopamine Antagonists: Medicines like metoclopramide may decrease the effects of both products on the gastrointestinal tract when taken together.
• Beta-adrenergic Agents: Concomitant use with beta-adrenergic agents may lead to an increase in heart rate.

---

Pharmacokinetic and Toxicity Interactions (Paracetamol component)

• Hepatotoxic Agents: The risk of liver damage is increased when paracetamol is used with alcohol, certain sleeping medicines, or medicines for epilepsy (e.g., glutethimide, phenobarbital, phenytoin, carbamazepine), and the antibiotic Rifampicin. Patients with existing liver or kidney dysfunction require close medical monitoring.
• Zidovudine (AZT): The concurrent use of paracetamol and AZT, an anti-AIDS medicine, may increase the potential for a decrease in white blood cell count (leukopenia); therefore, this combination should only be taken with medical advice.
• Absorption Rate: Medicines that slow gastric emptying, such as the antispasmodic propantheline, may decrease the rate of paracetamol absorption, resulting in a delayed onset of effect.
• Chloramphenicol: Use with the antibiotic chloramphenicol may increase the risk of toxicity by prolonging the half-life of chloramphenicol.

How Spazmol Plus Works: Mechanism of Action

Modulation of Smooth Muscle Signaling

One component (e.g., Drotaverine) acts as a selective inhibitor of the enzyme Phosphodiesterase type 4 (PDE4) found in smooth muscle cells of the gastrointestinal, biliary, and genitourinary tracts. This interaction blocks the hydrolysis of cyclic AMP (cAMP), leading to increased intracellular cAMP concentration. The resulting cascade interferes with the muscle's contractile apparatus, causing inhibition of the contractile proteins and decreased smooth muscle tone in visceral organs.

---

Central Pain Pathway Dampening

The second component (e.g., Metamizole) primarily acts within the Central Nervous System (CNS). Its metabolites function as inhibitors of Cyclooxygenase-3 (COX-3) and modulators of endogenous opioidergic and cannabinoid systems. This dual action alters central signal transmission by acting upon descending pain-suppression pathways, modifying the perception and transmission of pain signals centrally. The overall profile is characterized by the simultaneous modification of both muscle tone peripherally and pain signaling centrally.

How to Use Spazmol Plus

Spazmol Plus, a fixed-dose combination containing Hyoscine Butylbromide (10 mg) and Acetaminophen (500 mg), is administered via a specific route, with defined dose limits and frequency of use.

---

Official Administration Guidelines

Feature	Guideline
Route of Administration	The product is for oral administration.
Dosing Schedule	The standard single dose is 1 to 2 tablets. The maximum daily dose is strictly limited to 6 tablets.
Dosing Frequency	The medicine is taken in divided doses, up to 3 times daily.
Tablet Integrity	Tablets are to be swallowed whole with an adequate amount of water; they must not be crushed or chewed.

---

Population and Duration Constraints

The medicine is intended for acute, short-term symptomatic relief. It is not intended for continuous, long-term daily administration without medical re-evaluation.

The regimen is generally applicable to older adults without underlying renal or hepatic impairment. The use of the adult regimen is permitted in children 10 years and over, but the fixed-dose combination is not recommended for children under 10 years of age.

If a dose is missed, take the next scheduled dose at the correct time and do not double the dose to compensate.

Research evidence / Overview of Studies for Spazmol Plus

---

Evidence for Use in Recurrent Crampy Abdominal Pain

Spazmol Plus was studied in conditions characterized by recurrent crampy abdominal pain and fluctuating episodic manifestations. The available evidence includes short-term, randomized controlled trials (RCTs) comparing the combination against a placebo or the study of the individual drugs used alone. These studies explored outcomes related to physical discomfort, primarily by measuring changes in pain intensity and tracking a patient's overall global assessment of observed symptom change over defined time intervals. Research has explored whether measured outcomes differ between the combination and the study of the single active ingredient, but findings were mixed across the scientific literature.

Evidence for Use in Primary Dysmenorrhoea (Menstrual Cramping)

The combination was studied for its use in managing acute menstrual cramping. The research base includes RCTs, sometimes using a crossover design, as well as studies examining patient-reported experiences. Research examined outcomes reflecting daily functioning or activity level, such as interference with chores or sleep, in addition to measured changes in menstrual pain intensity. Studies reported documentation of the measured outcome differences in menstrual pain scores during the study period. However, evidence is limited when looking at the number of dedicated, large-scale studies that compare this specific combination to other treatments.

What is Still Uncertain About the Research

The scientific evidence highlights several areas where research is ongoing or where limited information is available. Long-term effects are not fully established, as follow-up durations were limited in many controlled trials, providing little insight into potential sustained changes or long-term usage patterns. Comparative evidence is lacking for whether the combination measured differently compared to using the individual active components separately or against other treatments for pain and spasm. Additionally, data for certain groups remain insufficient, particularly for groups like children or the elderly, where evidence often rests on general information rather than dedicated studies of this specific combination.

Key Studies & References National Agency of Drug and Food Control of Indonesia (BPOM) Assessment Report: Acetaminophen and Hyoscine Butylbromide (FDC)

Common questions about Spazmol Plus (FAQ)

Q: What kind of side effects do most people report when they search for Spazmol Plus reviews?

Regulatory documents classify side effects by how often they occur. Common reactions include dry mouth, an increased heart rate (tachycardia), and visual disturbances like blurred vision. Less common effects listed in the official profile include dizziness and abnormal sweating.

Q: How long after taking Spazmol Plus do people usually start to feel its effects?

The official information suggests that the antispasmodic component (Hyoscine Butylbromide) is expected to begin acting to relieve muscle spasms within 15 to 30 minutes after oral administration. This indicates the expected time frame for the onset of the therapeutic effects on muscle tension.

Q: Is there a concern about taking Spazmol Plus with alcohol?

Official warnings state that combining the medicine with alcohol may increase the risk of liver damage (hepatotoxicity). This warning is due to the presence of the pain-relieving component (paracetamol) in the fixed-dose combination.

Q: Can Spazmol Plus be safely taken by people who have heart conditions?

Official guidance advises caution for individuals with pre-existing heart conditions, particularly those prone to tachyarrhythmia, which is a type of fast or irregular heart rhythm. This information reinforces the need for individual risk assessment when the medicine is considered.

Q: Is it required to get lab tests while taking Spazmol Plus?

Regulatory documents describe the need for monitoring of blood count, kidney (renal), and liver function, particularly when the medicine is used over a prolonged period of time. This monitoring is intended to assess organ health during extended use.

Q: How long do the therapeutic effects of a single dose of Spazmol Plus typically last?

The regulatory guidelines state that the medicine is intended to be taken in divided doses, up to three times daily, as stated in the official dosing guidelines. This frequency is consistent with the duration of the drug's therapeutic effect.

Q: Does taking Spazmol Plus with food change how the drug works?

The official information states that tablets are to be swallowed whole with an adequate amount of water. There are generally no specific restrictions noted in regulatory documents regarding taking the medicine with food.

Q: Are there different requirements for using Spazmol Plus if you have kidney problems?

For patients with impaired kidney function, official documents emphasize that close medical monitoring is warranted. This is necessary because of how the paracetamol component is processed by the body, and the degree of impairment affects the specific precautions needed.

Q: What is the official statement about using Spazmol Plus during pregnancy?

Official information states that use during pregnancy is generally not recommended. This precaution is based on the fact that a potential risk to the developing fetus cannot be excluded due to limited clinical data available for the combination product.

Q: Do studies suggest Spazmol Plus is effective for long-term use?

Official guidance states the medicine is intended for acute, short-term symptomatic relief, and continued daily administration for extended periods is not recommended without medical re-evaluation. Clinical trials have primarily focused on short-term outcomes.

Q: Is Spazmol Plus considered a controlled substance in any major regions?

The active ingredients, Acetaminophen (a non-opioid analgesic) and Hyoscine Butylbromide (a peripheral anticholinergic), are not listed as controlled substances by major regulatory bodies. However, the medicine is typically a prescription-only product.

Q: What should I do if the side effects of Spazmol Plus feel worse than expected?

Official documents advise that if severe, unexplained abdominal pain persists or worsens, or if symptoms occur together with severe signs like fever, vomiting, or fainting, a healthcare professional should be consulted for guidance.

Q: Are there any food restrictions mentioned when taking Spazmol Plus?

Official patient information leaflets do not list specific food restrictions or dietary rules that must be followed while taking Spazmol Plus.

Q: Does Spazmol Plus contain a benzodiazepine or a similar substance?

The medicine is classified as a combination analgesic and antispasmodic agent. Its antispasmodic component (Hyoscine Butylbromide) is a peripheral anticholinergic and is not related to benzodiazepines or similar central nervous system depressants.

Q: Are there any long-term health risks associated with Spazmol Plus that are mentioned in official documents?

Official labels highlight the risk of severe liver damage associated with the paracetamol component if the maximum daily dose is exceeded. Regulatory guidance describes the need for medical monitoring of organ function when the medicine is used for prolonged periods.

Q: Is there a risk of dependency or withdrawal associated with Spazmol Plus?

The antispasmodic component is noted to have no evidence of being addictive or causing dependency. However, abrupt discontinuation of the analgesic component (paracetamol) after very prolonged, high-dose use may induce temporary withdrawal symptoms.

Q: Are there any warnings about combining Spazmol Plus with muscle relaxants?

The hyoscine component has anticholinergic properties. Official warnings state that concurrent use with other agents that possess anticholinergic effects, which can include certain muscle relaxants, may intensify common side effects like dry mouth and blurred vision.

How to Store and Dispose of Spazmol Plus?

This information is based on official government regulatory documents defining storage and disposal requirements.

Official Storage Conditions

The product must be stored under specific environmental constraints to maintain its stability and effectiveness:

• Temperature: Store at a temperature below 25°C.
• Container Protection: Keep the medicine in its original package.
• Child Safety: Always keep this medicine out of the reach and sight of children.

Official Disposal Rules

Proper disposal is required to prevent environmental harm and accidental exposure:

• Waste Medicines: Any unused medicinal product or waste material must be disposed of in accordance with local requirements.
• Environmental Protection: Do not dispose of this medicine via wastewater (e.g., do not flush down the toilet or drain).